Skip to main content
TipRanks
Go Ultimate75% OFF

Laboratorios Farmaceuticos Rovi (41L) Q2 2026 Earnings Report

4 Followers

DE:41L Q2 2026 EPS Results

Actual EPS
EUR 1.47
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
EUR 0.42

DE:41L Q2 2026 Revenue Results

Actual Revenue
EUR 191.67M
Expected Revenue
EUR 177.87M
Beat/Miss
Beat by +EUR 13.80M
YoY Revenue Growth
+20.02%

Earnings Announcement Details

Quarter
Q2 2026
Date
07/23/2026
Time
Before Open
Conference Call
Thursday, July 23, 2026
DE:41L Upcoming Earnings

Laboratorios Farmaceuticos Rovi's next earnings date is estimated for February 24, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Jul 23, 2026|% Change Since:27.88%|
Earnings Call Sentiment|Neutral

The call presented a mix of strong operational and financial positives (double‑digit revenue growth, 38% CDMO growth, improved gross margins, strong cash generation, strategic Phoenix acquisition and clinical progress) alongside material caveats: much of the headline profit uplift was driven by a one‑off EUR 62.4 million badwill, underlying EBITDA and EBIT declined year‑on‑year, SG&A and R&D rose sharply, and the heparin franchise still faces year‑on‑year declines despite recent Q2 improvement. Management maintained cautious full‑year guidance and flagged regulatory and contract timing risks. Overall the results show meaningful momentum in CDMO, cash flow and product development, but underlying operational profitability and cost pressures temper the outlook.

Company Guidance

ROVI reiterated its 2026 guidance, continuing to expect operating revenue to increase by a low- to mid‑single‑digit percentage versus 2025; it also narrowed its heparin outlook, now forecasting low‑molecular‑weight heparins to decline by a mid‑single‑digit percentage (improved from a prior high‑single‑digit decline) while bemiparin is expected to grow by a low single‑digit percentage in 2026 after a strong Q2 recovery (H1 bemiparin sales EUR 46.7m, enoxaparin biosimilar EUR 78.6m, total heparin sales EUR 130.1m, ~38% of operating revenue). The company confirmed continued CDMO expansion after CDMO revenue rose 38% to EUR 106.3m in H1 (Phoenix contributed ~EUR 13.8m and the BMS supply agreement provides a baseline ~USD 50m p.a.), expects SG&A (excluding Phoenix) to increase mid‑ to high‑single‑digits, is maintaining its investment plan (H1 CapEx EUR 30.4m), and highlighted ongoing growth drivers such as Okedi (H1 sales EUR 34m, +27% y/y) and ISM clinical progress.

  • Total Revenue GrowthTotal revenue increased 13% year‑on‑year to EUR 357.0 million in H1 2026; operating revenue rose 9% to EUR 344.2 million, driven mainly by CDMO strength.
  • CDMO Business AccelerationContract manufacturing (CDMO) revenue grew 38% to EUR 106.3 million in H1 2026, supported by restored capacity at Madrid and contribution from the Phoenix facility (EUR 13.8 million revenue from Phoenix in the period).
  • Improved Gross Profit and MarginGross profit increased 21% to EUR 237.1 million; gross margin improved by 6.5 percentage points to 68.9% (and excluding other income improved 3.0 pp to 65.2%), aided by CDMO mix, Okedi contribution and lower heparin raw material costs.
  • Phoenix Acquisition and One‑off GainAcquired injectable manufacturing facility in Phoenix (April 1); preliminary purchase price allocation generated a EUR 62.4 million bargain purchase gain (badwill) recorded as nonrecurring income, strengthening U.S. industrial footprint.
  • Strong Cash Generation and Net Cash PositionOperating cash flow increased to EUR 94.3 million (H1 2025: EUR 28.0 million); free cash flow rose to EUR 64.7 million (H1 2025: EUR 7.5 million). Gross cash EUR 130.2 million vs total debt EUR 107.7 million, resulting in net cash of EUR 22.5 million (vs net debt EUR 21.9 million at YE25).
  • Net Profit Increase (Including One‑off)Net profit reached EUR 84.4 million, up 113% year‑on‑year, primarily reflecting the nonrecurring badwill and favorable tax treatment of that item (effective tax rate 16.9% vs 20% prior year).
  • Specialty Product Momentum — OkediOkedi sales of EUR 34.0 million, up 27% year‑on‑year; management reiterates potential longer‑term peak sales target of EUR 100–200 million and reports broad uptake across multiple European markets.
  • Clinical Progress on ISM PlatformLetrozole SIE received FDA clearance to proceed with IND clinical investigations and Phase III recruitment expected to start in Q3 2026; Risperidone QUAR delivered strong Phase I results and is progressing to Phase II with enrollment expected in Q4 2026.
  • Heparin Franchise Stabilization SignsManagement improved outlook for low molecular weight heparins (LMWH): expected decline revised from high single‑digit to mid single‑digit for 2026; bemiparin international sales recovered strongly in Q2 (up 52% vs Q2 2025 and >3x vs Q1 2026) and bemiparin expected to grow low single‑digit for full year.

DE:41L Earnings History

DE:41L earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 24, 20272026 (Q4)―-0.83――
Nov 05, 20262026 (Q3)―1.531.1335.19% (+0.40)
Jul 23, 20262026 (Q2)―1.470.42246.57% (+1.04)
May 06, 20262026 (Q1)―0.180.35-47.74% (-0.17)
Feb 25, 20262025 (Q4)―0.830.4682.49% (+0.38)
Nov 06, 20252025 (Q3)―1.130.8631.86% (+0.27)
Jul 24, 20252025 (Q2)―0.420.86-50.81% (-0.44)
May 08, 20252025 (Q1)―0.350.2922.49% (+0.07)
Feb 25, 20252024 (Q4)―0.460.99-54.02% (-0.54)
Nov 07, 20242024 (Q3)―1.360.9839.47% (+0.39)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed